New hope for Tough-to-Treat lymphoma: Two-Drug combo enters Mid-Stage trial

NCT ID NCT06534437

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing a new drug called MEN1703, both alone and combined with another drug called glofitamab, in 178 adults with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The study aims to see if the drugs are safe and can shrink tumors. Participants are split into two groups: those who have not tried a certain type of immunotherapy, and those who have exhausted all standard options.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MEN1703 (Dapolsertib hydrochloride) and Glofitamab

What this could lead to

If successful, this combination could offer a new treatment option for patients with aggressive B-cell lymphoma who have run out of standard therapies.

What could go wrong

This is an early Phase 2 trial with a small number of participants. The drugs may cause side effects, and it is not yet known if they will work better than existing treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA,B CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Aggression aggressive B-cell non-Hodgkin lymphoma B-cell non-Hodgkin lymphoma non-Hodgkin lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • APHP - Hôpital Pitié-Salpêtrière

    RECRUITING

    Paris, 75651, France

    Contact

  • Aidport Sp. z o.o.

    RECRUITING

    Skórzewo, Poland

    Contact

  • Beatson West of Scotland Cancer Centre

    RECRUITING

    Glasgow, United Kingdom

    Contact

  • CHU Montpellier - Hôpital Saint Eloi

    RECRUITING

    Montpellier, 34490, France

    Contact

  • CHU de Bordeaux - Hôpital Haut-Lévêque

    RECRUITING

    Pessac, 33600, France

    Contact

  • CHU de Lille - Hôpital Claude Huriez

    RECRUITING

    Lille, France

    Contact

  • CHU de Limoges - CHU Dupuytren

    RECRUITING

    Limoges, 87042, France

    Contact

  • Centre Hospitalier Le Mans

    RECRUITING

    Le Mans, 72037, France

    Contact

  • Clinica Universidad De Navarra

    RECRUITING

    Madrid, 28027, Spain

    Contact

  • Clinica Universidad De Navarra

    RECRUITING

    Pamplona, 31008, Spain

    Contact

  • Hospices Civils De Lyon - Hôpital Lyon Sud

    RECRUITING

    Lyon, 69310, France

    Contact

  • Hospital Clínico Uni versitario Virgen de la Arrixaca

    NOT_YET_RECRUITING

    Murcia, 30120, Spain

    Contact

  • Hospital Universitari Vall D Hebron

    RECRUITING

    Barcelona, 08035, Spain

    Contact

  • Hospital Universitario De Navarra

    RECRUITING

    Pamplona, 31008, Spain

    Contact

  • Hospital Universitario De Salamanca

    RECRUITING

    Salamanca, 37007, Spain

    Contact

  • Hospital Universitario Miguel Servet

    NOT_YET_RECRUITING

    Zaragoza, Spain

    Contact

  • Hospital Universitario Puerta de Hierro Majadahonda

    NOT_YET_RECRUITING

    Madrid, Spain

    Contact

  • Hospital Universitario Virgen De La Macarena

    RECRUITING

    Seville, 41009, Spain

    Contact

  • IN-VIVO Bydgoszcz Sp. z o.o.

    RECRUITING

    Bydgoszcz, Poland

    Contact

  • Klinika Hematologii I Transplantologii Uck

    NOT_YET_RECRUITING

    Gdansk, Poland

    Contact

  • Lux Med Onkologia Sp. z o.o.

    RECRUITING

    Warsaw, Poland

    Contact

    Contact

  • MD Anderson Cancer Center

    RECRUITING

    Madrid, 28033, Spain

    Contact

  • Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie, Państwowy Instytut Badawczy

    RECRUITING

    Gliwice, Poland

    Contact

    Contact

  • Plymouth Hospitals NHS Trust

    RECRUITING

    Plymouth, United Kingdom

    Contact

  • Pratia Hematologia Sp. z o.o.

    RECRUITING

    Katowice, Poland

    Contact

    Contact

  • Pratia MCM Kraków

    RECRUITING

    Krakow, Poland

    Contact

    Contact

  • SP ZOZ Szpital Uniwersytecki w Krakowie

    NOT_YET_RECRUITING

    Krakow, Poland

    Contact

  • St George's Hospital

    RECRUITING

    Tooting, United Kingdom

    Contact

  • Szpital Kliniczny Ministerstwa Spraw Wewnętrznych i Administracji z Warmińsko-Mazurskim Centrum Onkologii w Olsztynie

    RECRUITING

    Olsztyn, Poland

    Contact

    Contact

  • Szpitale Pomorskie Sp. z o.o.

    RECRUITING

    Gdynia, Poland

    Contact

  • The Christie NHS Foundation Trust

    RECRUITING

    Manchester, United Kingdom

    Contact

  • The Royal Marsden Hospital

    NOT_YET_RECRUITING

    London, United Kingdom

    Contact

  • The Royal Marsden Hospital

    NOT_YET_RECRUITING

    Sutton, United Kingdom

    Contact

  • Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej

    RECRUITING

    Biała Podlaska, Poland

    Contact

    Contact

  • Wojewódzki Szpital Zespolony im. L. Rydygiera w Toruniu

    RECRUITING

    Torun, Poland

    Contact

    Contact

  • Wojskowy Instytut Medyczny - Państwowy Instytut Badawczy

    RECRUITING

    Warsaw, Poland

    Contact

    Contact